The document summarizes a presentation given by Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines (ASBM), about biosimilars and challenges in bringing them to patients. Some key points: - Biosimilars provide increased treatment options and potential cost savings compared to reference biologics, but developing and approving biosimilars faces more challenges than generic drugs due to biologics' larger and more complex molecular structure. - Physician confidence and acceptance is important for biosimilar use, but indication extrapolation and lack of long-term clinical data are concerns that could limit adoption. - Through surveys of physicians worldwide, ASBM is providing data on physician perspectives to regulators